Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712414 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL12818386 | 0.78 | CYP2D6 (0.39) | CYP2D6KDM4E | |
| Hydrochloric Acid SCHEMBL2188465 | 0.76 | — | — | |
| SCHEMBL8858904 | 0.75 | — | — | |
| SCHEMBL13632467 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL7805756 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL9543054 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL3062035 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL7047737 | 0.73 | — | — | |
| SCHEMBL23997576 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150165380-A1 | DRAW SOLUTES COMPRISING ALKYL AMMONIUM SALT COMPOUNDS | LOTTE CHEMICAL CORPORATION (KR) | 2015-06-18 | — | — | US | claimed |
| US-20110189102-A1 | COATED QUANTUM DOTS AND METHODS OF MAKING AND USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-04 | — | — | US | claimed |
| WO-2009100203-A1 | COATED QUANTUM DOTS AND METHODS OF MAKING AND USING THEREOF | EMORY UNIVERSITY (US) | 2009-08-13 | — | — | WO | claimed |
| US-12325715-B2 | Fluorous metal chelates compositions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-10 | — | — | US | disclosed |
| EP-3831394-B1 | CROSS-LINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE | SEIKAGAKU KOGYO CO LTD (JP) | 2022-12-21 | — | — | EP | disclosed |
| US-20220033424-A1 | FLUOROUS METAL CHELATES COMPOSITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-02-03 | — | — | US | disclosed |
| US-11207345-B2 | Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease | SEIKAGAKU CORPORATION (JP) | 2021-12-28 | — | — | US | disclosed |
| EP-3831394-A1 | CROSS-LINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE | Seikagaku Corporation (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-20210052634-A1 | CROSSLINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE | SEIKAGAKU CORPORATION (JP) | 2021-02-25 | — | — | US | disclosed |
| US-10716804-B2 | Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease | SEIKAGAKU CORPORATION (JP) | 2020-07-21 | — | — | US | disclosed |
| US-10696801-B2 | Hydrate inhibitor carrying hydrogel | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2020-06-30 | — | — | US | disclosed |
| US-20180265647-A1 | HYDRATE INHIBITOR CARRYING HYDROGEL | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL REASEARCH ORGANISATION (AU) | 2018-09-20 | — | — | US | disclosed |
| EP-3303510-A1 | HYDRATE INHIBITOR CARRYING HYDROGEL | Commonwealth Scientific and Industrial Research Organisation (AU) | 2018-04-11 | — | — | EP | disclosed |
| US-20170368093-A1 | CROSSLINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE | SEIKAGAKU CORPORATION (JP) | 2017-12-28 | — | — | US | disclosed |
| EP-3246037-A1 | CROSSLINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE | Seikagaku Corporation (JP) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016187672-A1 | HYDRATE INHIBITOR CARRYING HYDROGEL | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-12-01 | — | — | WO | disclosed |
| US-20150165380-A1 | DRAW SOLUTES COMPRISING ALKYL AMMONIUM SALT COMPOUNDS | LOTTE CHEMICAL CORPORATION (KR) | 2015-06-18 | — | — | US | disclosed |
| US-20140024047-A1 | COATED QUANTUM DOTS AND METHODS OF MAKING AND USING THEREOF | EMORY UNIVERSITY (US) | 2014-01-23 | — | — | US | disclosed |
| US-20110189102-A1 | COATED QUANTUM DOTS AND METHODS OF MAKING AND USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-04 | — | — | US | disclosed |
| WO-2009100203-A1 | COATED QUANTUM DOTS AND METHODS OF MAKING AND USING THEREOF | EMORY UNIVERSITY (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150165380-A1 | DRAW SOLUTES COMPRISING ALKYL AMMONIUM SALT COMPOUNDS | SLC34A3, SLC43A1, SLC34A1 | CYP2D6 4534/4885KDM4E 3450/4885TAAR1 1711/4885 |
| US-20220033424-A1 | FLUOROUS METAL CHELATES COMPOSITIONS | KAT6A, SLC6A12, SLC6A6 | CYP2D6 3662/4885KDM4E 1582/4885TAAR1 475/4885 |
| US-12325715-B2 | Fluorous metal chelates compositions | KAT6A, SLC6A12, SLC6A6 | CYP2D6 3662/4885KDM4E 1582/4885TAAR1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.